[go: up one dir, main page]

MX2017001638A - Molecula portadora para antigenos. - Google Patents

Molecula portadora para antigenos.

Info

Publication number
MX2017001638A
MX2017001638A MX2017001638A MX2017001638A MX2017001638A MX 2017001638 A MX2017001638 A MX 2017001638A MX 2017001638 A MX2017001638 A MX 2017001638A MX 2017001638 A MX2017001638 A MX 2017001638A MX 2017001638 A MX2017001638 A MX 2017001638A
Authority
MX
Mexico
Prior art keywords
carrier molecule
conjugate
antigens
antigen
spb1
Prior art date
Application number
MX2017001638A
Other languages
English (en)
Inventor
Grandi Guido
Maione Domenico
Margarit Y Ros Immaculada
Cozzi Roberta
Daniela Rinaudo Cira
Berti Francesco
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2017001638A publication Critical patent/MX2017001638A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona un conjugado que comprende un antígeno y una molécula portadora, en el que la molécula portadora comprende un antígeno BP-2a y un antígeno spb1. BP-2 y spb1 son antígenos de Streptococcus agalactiae. El conjugado se puede usar en un método para elevar la respuesta inmunológica en un mamífero, comprendiendo el método administrar el conjugado al mamífero. También se proporcionan composiciones farmacéuticas, en particular vacunas, que comprenden el conjugado.
MX2017001638A 2014-08-05 2015-08-05 Molecula portadora para antigenos. MX2017001638A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179945 2014-08-05
PCT/EP2015/068012 WO2016020413A1 (en) 2014-08-05 2015-08-05 Carrier molecule for antigens

Publications (1)

Publication Number Publication Date
MX2017001638A true MX2017001638A (es) 2017-04-27

Family

ID=51298571

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001638A MX2017001638A (es) 2014-08-05 2015-08-05 Molecula portadora para antigenos.

Country Status (16)

Country Link
US (1) US10245310B2 (es)
EP (1) EP3177324A1 (es)
JP (1) JP2017523985A (es)
KR (1) KR20170039709A (es)
CN (1) CN108064174A (es)
AR (1) AR101455A1 (es)
AU (1) AU2015299008B2 (es)
BE (1) BE1022792B1 (es)
BR (1) BR112017002183A2 (es)
CA (1) CA2957118A1 (es)
EA (1) EA201790239A1 (es)
IL (1) IL250238A0 (es)
MX (1) MX2017001638A (es)
SG (1) SG11201700673RA (es)
WO (1) WO2016020413A1 (es)
ZA (1) ZA201700824B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
MA47223A (fr) 2016-12-30 2019-11-06 Sutrovax Inc Conjugués polypeptide-antigène avec des acides aminés non naturels
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL302880A (en) * 2017-04-04 2023-07-01 Avidea Tech Inc Peptide-based ingredients, production methods, and their uses for inducing an immune response
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
WO2019217665A1 (en) * 2018-05-09 2019-11-14 West Virginia University Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
WO2020010000A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020009993A1 (en) * 2018-07-04 2020-01-09 Sutrovax, Inc. Improvements in immunogenic conjugates
CN108840914B (zh) * 2018-08-13 2022-07-01 内蒙古民族大学 一种具有免疫原性的多肽、其抗体的制备方法以及用途
SG11202110803YA (en) 2019-04-02 2021-10-28 Vaxcyte Inc Optimized cell-free synthesis of invasion plasmid antigen b and related compositions and methods of use
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20230250142A1 (en) * 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
EP4165065A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Gbs ferritin nanoparticles
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用
GB202215634D0 (en) * 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575548A1 (en) * 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006069200A2 (en) * 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US20100150943A1 (en) * 2006-07-26 2010-06-17 Novartis Ag Immunogenic compositions for gram positive bacteria
GB0802503D0 (en) 2008-02-11 2008-03-19 Novartis Ag Hybrid polypeptide
CA2749367A1 (en) * 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
GB201003333D0 (en) * 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201114923D0 (en) * 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
RU2014138418A (ru) * 2012-02-24 2016-04-10 Новартис Аг Белки пилей и композиции

Also Published As

Publication number Publication date
ZA201700824B (en) 2019-07-31
KR20170039709A (ko) 2017-04-11
WO2016020413A1 (en) 2016-02-11
EP3177324A1 (en) 2017-06-14
EA201790239A1 (ru) 2017-07-31
AU2015299008A1 (en) 2017-02-23
US10245310B2 (en) 2019-04-02
AR101455A1 (es) 2016-12-21
CA2957118A1 (en) 2016-02-11
IL250238A0 (en) 2017-03-30
JP2017523985A (ja) 2017-08-24
BE1022792B1 (fr) 2016-09-06
SG11201700673RA (en) 2017-02-27
US20170224803A1 (en) 2017-08-10
AU2015299008B2 (en) 2018-08-02
BE1022792A1 (fr) 2016-09-06
BR112017002183A2 (pt) 2018-01-16
CN108064174A (zh) 2018-05-22

Similar Documents

Publication Publication Date Title
MX2017001638A (es) Molecula portadora para antigenos.
IL294146A (en) Antibody conjugates against cmet with drug and methods of using them
IL283058B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
MX354924B (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
PH12015500977A1 (en) Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
IL255106A0 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
SG10201803042PA (en) Anti-tim-3 antibodies
MY170719A (en) Antibody-drug conjugates
MX421186B (es) Constructos de anticuerpos.
MX2015016240A (es) Metodos para tratar una tauopatia.
MY191539A (en) Streptococcal vaccine
EP3010340A4 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
WO2014179184A8 (en) Compositions for inducing immune tolerance to coagulation factor proteins
HK1224187A1 (zh) 针对药物成瘾的疫苗组合物
HK1238261A1 (en) Novel anti-mfi2 antibodies and methods of use
HK1232458A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma